News/ News/ R&D FDA fast-tracks AbbVie’s spinal injury drug Richard Staines AbbVie, fda, R&D, spinal injury 0 Comment The FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be Share X FDA fast-tracks AbbVie’s spinal injury drug https://pharmaphorum.com/news/fda-fast-tracks-abbvies-spinal-injury-drug/